Search

A recent study conducted at the University of Washington examined the impact of insulin sensitivity and beta-cell function on glycemic outcomes in response to dual therapy for diabetes. The study found that higher insulin sensitivity and C-peptide responses were associated with better initial treatment responses and lower risk of glycemic failure. These associations varied depending on the type of treatment received, with sitagliptin showing greater impact on initial HbA(1c) reduction compared to other therapies. The research, which has been peer-reviewed, provides valuable insights into the effectiveness of different antidiabetic agents in managing diabetes. [Extracted from the article]

Researchers at Shanghai Jiao Tong University School of Medicine have conducted a study on kidney cancer, specifically focusing on the mechanisms and treatment of sunitinib resistance in renal cell carcinoma (RCC). The study highlights the increasing morbidity and mortality rates of RCC, emphasizing the importance of targeted therapies like sunitinib in controlling tumor progression. However, the research also addresses the challenge of sunitinib resistance in RCC patients, aiming to provide insights for developing more effective treatment strategies. This study offers valuable information for individuals interested in advancements in RCC treatment and overcoming drug resistance. [Extracted from the article]

A recent study conducted at Jawaharlal Nehru Medical College in India focused on metabolic-associated steatotic liver disease (MASLD), which is a common cause of chronic liver disease globally. The research highlighted the potential benefits of using antiplatelet drugs, specifically aspirin, in managing MASLD by reducing hepatic inflammation, oxidative stress, and insulin resistance, potentially preventing hepatic fibrosis progression. The study emphasized lifestyle modifications and treating coexisting conditions like obesity, hyperlipidemia, insulin resistance, and type 2 diabetes as part of the current management strategies for MASLD. For more information, the full article can be accessed through the European Journal of Gastroenterology & Hepatology. [Extracted from the article]

Researchers at Ain Shams University conducted a study on the potential benefits of combining Bacillus Calmette-Guerin (BCG) vaccine with liraglutide and probiotics in treating Type 1 diabetes in rats. The study found that this combination showed promise in suppressing pyroptosis of pancreatic islets and improving glucose homeostasis parameters. The research suggests that this combined therapy could be a promising approach in managing Type 1 diabetes mellitus by targeting the pancreatic TXNIP/NLRP3 signaling pathway. [Extracted from the article]

A recent study conducted at the University of Montreal compared the efficacy and safety of weekly somatrogon injections with daily somatropin injections in treating children with growth hormone deficiency. The research found that the growth rate of children treated with weekly somatrogon was similar to that of children treated with daily somatropin, indicating no significant difference in efficacy. Additionally, the safety profile of weekly somatrogon injections was comparable to that of daily somatropin injections. The study was published in The Journal of Clinical Endocrinology & Metabolism and aimed to provide valuable insights for healthcare providers treating growth hormone deficiency in children. [Extracted from the article]

Researchers at Bogomolets National Medical University in Kyiv, Ukraine, have published a study on the pathogenetic basis of treating endothelial dysfunction with metformin in patients with diabetes. The study highlights the impact of hyperglycemia on cardiovascular health and the beneficial effects of metformin in reducing insulin resistance and improving vascular health. The research suggests that metformin could be a safe and effective treatment for hyperglycemia and cardiovascular diseases, particularly in addressing endothelial dysfunction and atherosclerosis. For more information, the full article can be accessed in the Mižnarodnij Endokrinologicnij Žurnal. [Extracted from the article]

Researchers from the Russian Academy of Sciences conducted a study on the efficacy of combining Metformin and intranasal insulin to treat rats with cafeteria diet-induced obesity. The study found that this combination normalized body weight, restored glucose homeostasis, and improved insulin sensitivity in the rats. The research concluded that a combined course of Metformin and low-dose intranasal insulin showed promise in correcting metabolic and hormonal indices in diet-induced obesity without negative effects on the thyroid axis. [Extracted from the article]

Researchers at Santhiram College of Pharmacy in India conducted a case report on the combination treatment of a deep diabetic toe ulcer using collagenase-santyl dressings and antibiotics. The study focused on a 58-year-old male patient with a foot ulcer who showed improvement with the suggested treatment, including enzymatic debridement therapy and antibiotics. The research concluded that the use of collagenase-santyl dressings and antibiotics can aid in successful wound healing and prevent complications in diabetic foot ulcers. For more information, readers can refer to the Journal of Holistic Integrative Pharmacy. [Extracted from the article]

A study published in the American Journal of Obstetrics and Gynecology explores the impact of metformin on fetal growth when given to pregnant women. Metformin, commonly used to control blood sugar, has been found to restrict fetal growth, particularly affecting the kidneys, liver, and other organs. This research raises concerns about potential long-term health risks for children exposed to metformin in utero, such as obesity and insulin resistance. Further studies are needed to fully understand the effects of metformin on fetal development and metabolism, especially in the context of addressing obesity and diabetes epidemics. [Extracted from the article]

The article explores the molecular mechanisms underlying aging and infection in various organs of mice, focusing on gene dysregulation and immune system activation. By using spatial transcriptomics, researchers identified shared activation of the complement pathway and serine protease inhibitors in aging and infection. The study provides a comprehensive atlas for studying aging and infection at a spatiotemporal resolution, offering insights for future drug discovery and mechanistic studies. This preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted at Nagoya City University compared the effects of insulin and metformin on inflammatory markers in patients with type 2 diabetes mellitus (T2DM). The study found that T2DM patients treated with insulin had higher rates of microvascular complications, such as retinopathy and neuropathy, compared to those treated with metformin. Additionally, inflammatory markers were lower in the insulin group, suggesting distinct differences in systemic complications between the two treatment groups. Further research is needed to understand these observations and optimize treatment strategies for T2DM patients. [Extracted from the article]

A recent study from the University of Porto in Portugal explores the potential of antimicrobial peptides (AMPs) found in marine cephalopods' salivary glands as a source for novel therapeutic agents. By using in silico proteolysis, researchers identified over 9 million nonredundant peptides from 14 cephalopod species, screening for antimicrobial activity while ensuring safety and uniqueness compared to known AMPs. The study resulted in the release of five relevant AMP datasets, providing valuable resources for peptide drug developers. This research offers insights into the potential of cephalopods as a source of AMPs for combating antimicrobial resistance. [Extracted from the article]

A recent study conducted at the National Autonomous University of Mexico (UNAM) explored the effects of gonadotropin-releasing hormone (GnRH) and growth hormone (GH) treatments on motor function recovery in rats with thoracic spinal cord injury (SCI). The research found that chronic administration of GnRH and GH led to increased expression of neurotrophic and synaptogenic activity genes, as well as improvements in synaptic markers and myelin integrity. However, the study also noted that the combined treatment with GH appeared to inhibit neuromotor recovery, highlighting the complexity of hormonal regulation post-SCI and the need for further investigation into optimal therapeutic strategies for patients with spinal cord lesions. [Extracted from the article]

A study conducted by New York Medical College focuses on the use of teplizumab therapy to delay the onset of Type 1 Diabetes. Type 1 diabetes mellitus is an autoimmune disease that affects the insulin-producing pancreatic beta cells, leading to significant morbidity and mortality. Teplizumab, a monoclonal antibody, has been approved by the FDA as the first preventative treatment for Type 1 Diabetes after three decades of research and development. The study provides an overview of the discovery, mechanism of action, and clinical trials of teplizumab. [Extracted from the article]

Researchers at the University of Queensland have developed a pH-sensitive, naturally crosslinked alginate-chitosan hydrogel for drug delivery applications. This hydrogel system shows promise in targeted and controlled release of therapeutic agents, particularly in the colon, where it achieved high drug release efficiency in a simulated pH environment. The study highlights the potential of this hydrogel as a drug delivery carrier for gastrointestinal treatments, offering enhanced efficacy for current therapeutic options. [Extracted from the article]

Researchers from the Department of Pharmacy in Haikou, China, have conducted a study on the biological activities of crude venom extracted from five species of South China Sea anemones. The study found that the venom from Heteractis magnifica exhibited the most potent activities, including analgesic, hemolytic, and cytotoxic effects. These findings have implications for the development of novel drugs, including anticancer medications and biopesticides, utilizing resources from South China Sea anemones. For more information, the full article can be accessed for free at the Frontiers in Marine Science website. [Extracted from the article]

A recent study conducted at Toulouse University Hospital in France examined the effectiveness and safety of insulin glargine 300 U/mL (Gla-300) therapy in insulin-naive individuals with type 2 diabetes. The study analyzed patient data from 2381 participants and found that Gla-300 was effective and safe in improving HbA1c levels, regardless of diabetes duration. The research concluded that initiating Gla-300 in participants with a diabetes duration of less than 4 years led to greater improvements in HbA1c levels. [Extracted from the article]

Researchers at the Medical University of Lodz conducted a study on the effects of clozapine and olanzapine, commonly used antipsychotic medications, on insulin resistance in human preadipocytes. The study found that both drugs altered the expression of key genes and epigenetic regulators in the insulin pathway, potentially contributing to insulin resistance in adipose tissue. This research provides valuable insights into the metabolic effects of these medications. [Extracted from the article]

Researchers from the University of Auckland in New Zealand conducted a study on the impact of a specific genetic variant, rs8187715, on metformin pharmacokinetics and insulin sensitivity in C57BL/6J mice. The variant was found to accelerate metformin uptake rate in vivo, leading to improved insulin sensitivity acutely but no increased effect with longer-term dosing. This variant was prevalent in Māori and Pacific peoples, suggesting it could be a population-specific pharmacogenetic marker for guiding metformin therapy in these groups. The study was published in Diabetologia and was supported by various institutions and funding sources. [Extracted from the article]

Researchers at the Catholic University of Korea conducted a study to assess the use of a heparin-calibrated anti-factor Xa assay for measuring direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and edoxaban. The study aimed to determine if the antidote treatment decision level for DOACs could be established using unfractionated heparin (UFH)/low molecular weight heparin (LMWH)-calibrated AXA. The findings suggest that UFH/LMWH-calibrated AXA may be effective in determining the presence of DOACs at the cutoff level for antidote treatment in rivaroxaban and apixaban, but not in edoxaban. The research has been peer-reviewed and published in Clinical Laboratory. [Extracted from the article]

A study conducted at the University of Miami analyzed the incidence of surgical intervention in veterans treated with Collagenase Clostridium Histolyticum (CCH) for Peyronie's disease. The research found that only 3.3% of patients received secondary surgical therapy after CCH, with residual curvature being the most common reason for additional treatment. The study highlights the need for further research and treatment options for patients who do not respond effectively to CCH. [Extracted from the article]

A study conducted at the Institute of Pathology and Southwest Cancer Center explored the potential of allicin in reversing Taxol resistance in non-small cell lung cancer (NSCLC). The research found that allicin effectively inhibited cell proliferation, induced apoptosis, and reversed Taxol resistance by inhibiting P-gp and Cathepsin B activity, disrupting the lysosomal-autophagy pathway. These findings suggest that allicin has the potential for cancer treatment and drug development. For more information, the full article is available in Food Frontiers, published by Wiley. [Extracted from the article]

A recent study conducted by researchers at Seoul National University College of Medicine focused on atrial fibrillation and the use of apixaban therapy. The study examined the plasma concentration of apixaban and thrombin generation assay parameters in patients with atrial fibrillation who had dose reduction criteria for apixaban. The findings indicated that off-label reduced-dose apixaban resulted in lower apixaban levels compared to on-label standard dose and on-label reduced-dose apixaban, emphasizing the importance of adhering to dose-reduction criteria for optimal therapeutic outcomes. The study highlighted the significance of maintaining appropriate apixaban levels and the need for further research on the impact of under-dosing on clinical outcomes. [Extracted from the article]

Research from Changchun University of Chinese Medicine explores the potential of peptide drugs for treating type 2 diabetes through oral administration. The study highlights the challenges of oral utilization of peptide drugs due to degradation and absorption issues, proposing nano-formulation carriers as a solution. This research offers new insights into alternative treatment options for type 2 diabetes, emphasizing the importance of improving the oral delivery of peptide drugs. [Extracted from the article]

The article discusses the emulation of the effects of injectable semaglutide on cardiovascular outcomes in individuals with Type 2 diabetes through a large-scale trial. The study aims to understand the types of clinical questions that can be confidently analyzed using real-world data and how to implement such studies. The trial, NCT06659744, is a non-randomized, non-interventional study that emulates the SUSTAIN6 trial to evaluate the effects of injectable semaglutide versus placebo on cardiovascular safety in patients with Type 2 diabetes. The study design includes new-user active comparative analysis comparing semaglutide with sitagliptin as an active-comparator proxy for placebo. [Extracted from the article]

A recent report from the University Gadjah Mada discusses the global research trends in antiviral peptide (AVP) studies from 1951 to 2022. AVPs are being explored as potential alternatives to traditional antiviral drugs due to concerns about drug resistance. The analysis, based on data from the Scopus database, reveals that the United States leads in AVP-related publications, followed by China, Germany, and the United Kingdom. The study highlights key themes in AVP research, such as virology, genetics, protease inhibitors, and viral entry, providing valuable insights for future research in the field. [Extracted from the article]

A recent study conducted at Western University in Canada explored the process of alpha- to beta-cell transdifferentiation in neonatal and adult mouse pancreas following a partial reduction in beta-cells using streptozotocin. The research found that transdifferentiation of cells occurred in mice after a moderate depletion in beta-cell mass, leading to a partial recovery of beta-cell mass in adult mice. The study highlights the potential for therapeutic interventions to promote cell transdifferentiation and aid in the recovery of beta-cell mass in cases of reduced beta-cell abundance. [Extracted from the article]

A recent report from Lodz University of Technology discusses the potential of stapled peptides as therapeutics for diabetes and metabolic diseases. The research highlights the enhanced stability, cellular permeability, and binding affinity of these peptides, which target crucial molecular pathways associated with glucose metabolism, insulin secretion, and food intake. The study also addresses challenges in developing stapled peptides, such as structural stability and potential side effects. Financial support for this research came from the National Science Centre in Poland. [Extracted from the article]

A recent study conducted at Lanzhou University in Gansu, China, explored the impact of using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the survival of hypertensive patients with cancer. The study found that patients with certain types of cancer who used ACEIs or ARBs had significantly increased survival times, except for those with breast cancer and uroepithelial carcinoma. The research suggests that further investigation into the mechanisms of action of these drugs could lead to novel therapeutic options and improve the prognosis of cancer patients in the future. [Extracted from the article]

Researchers at Mansoura University have conducted a study on Enterococcus faecalis, a bacterium with widespread antimicrobial resistance. The study focused on targeting the fsr quorum sensing system of E. faecalis as a potential therapeutic strategy to combat antibiotic-resistant infections. Polidocanol, a compound tested in the study, showed promise in inhibiting virulence factors and biofilm formation in E. faecalis, making it a potential option for treating infections caused by this bacterium. The research was supported by Mansoura University and published in BMC Microbiology. [Extracted from the article]

Researchers from Comenius University in Bratislava, Slovakia, have conducted studies on the therapeutic drug monitoring of peptide antibiotics. They emphasize the importance of rational use of antimicrobial peptides to combat diseases caused by multidrug-resistant bacterial pathogens. The research highlights the need for optimized dosing strategies to minimize resistance and ensure the efficacy of antibiotics in clinical practice. This study provides an overview of approved antimicrobial peptides and current trends in their analysis for therapeutic drug monitoring purposes, with a focus on methods with potential clinical outcomes. [Extracted from the article]

The article discusses a Phase 3 clinical trial evaluating the efficacy and safety of combination therapy for individuals with type 2 diabetes mellitus and essential hypertension. The trial aims to demonstrate the superiority of a specific combination therapy compared to monotherapy in reducing blood pressure and hemoglobin A1c levels. The study involves various outcome measures related to glycemic parameters and blood pressure changes. Recruitment for the trial has not yet begun, with an enrollment target of 221 participants and a completion date set for December 1, 2026. [Extracted from the article]

A recent study conducted at the University Hospital of Clermont-Ferrand in France focused on the use of direct oral anticoagulants (DOACs) in patients with hemophilia A (HA) to manage cardiovascular diseases. The study aimed to evaluate the hemostatic balance of HA plasma containing DOACs and emicizumab, supplemented by factor VIII. Findings indicated that factor VIII can safely counter the anticoagulant effect of DOACs at specific doses, and the thrombin generation assay was effective in monitoring plasma with anti-FXa DOACs. The study provides valuable insights into managing hemostatic challenges in patients with HA receiving multiple treatments. [Extracted from the article]

Korean biopharma GemVax & KAEL has stumbled on its quest to develop new therapies for neurodegenerative diseases. [ABSTRACT FROM AUTHOR]

A study conducted at Zhejiang Chinese Medicine University in China explored the mechanisms underlying chemotherapy-induced nausea and vomiting (CINV) by investigating the role of substance P (SP) and protein kinase A (PKA) signaling. The researchers found that the gut microbial lipid metabolite 14(15)-EpETE inhibits SP release by targeting GCG/PKA signaling, ultimately alleviating CINV symptoms in rats. This research has been peer-reviewed and published in the Journal of Microbiology and Biotechnology. For more information, readers can contact the authors at Zhejiang Chinese Medicine University. [Extracted from the article]

A study published in Quantitative Biology explores the electrostatic interactions of adenosine triphosphate (ATP) with insulin-degrading enzyme (IDE) using quantum mechanics/molecular mechanics (QM/MM) and molecular dynamics (MD) methods. The research aims to understand how ATP negatively regulates IDE in clearing Amyloid beta (Ab) peptides, which are linked to Alzheimer's disease (AD) progression. By revealing the molecular and quantum-level details of ATP-IDE interactions, the study provides insights crucial for developing IDE inhibitors to target ATP interactions and potentially slow down AD advancement. The findings highlight the importance of early therapeutic interventions to address the growing impact of AD, which is projected to affect millions by 2060. [Extracted from the article]

Researchers from the University of Guadalajara conducted a study to evaluate the effects of propolis and metformin on glycemic control in patients with type 2 diabetes mellitus. The study involved a double-blind, randomized, placebo-controlled clinical trial with 36 patients. Results showed that both propolis and metformin groups experienced significant reductions in fasting plasma glucose and 2-hour postload glucose levels, as well as improvements in insulin sensitivity. The research concluded that propolis and metformin were effective in reducing glucose levels and improving insulin sensitivity compared to a placebo. [Extracted from the article]

A recent study conducted at the National Research Centre in Giza, Egypt, compared the antidiabetic potential of magnetized water, metformin, and their combination in a rat model of Type II Diabetes. The research found that magnetized water supplementation could reduce hyperglycemia, restore antioxidant balance, reduce inflammation, and alter genes involved in glucose metabolism, suggesting it may be used as an adjuvant in Type II Diabetes management. The study provides new insights into the potential benefits of magnetized water consumption in reducing Type II Diabetes complications. [Extracted from the article]

A study conducted at the University of Piemonte Orientale in Novara, Italy, examined the impact of different diabetes statuses on the outcomes of patients with atrial fibrillation (AF) treated with edoxaban. The research found that diabetic patients requiring insulin therapy had a higher risk of thromboembolic events and all-cause mortality compared to those without diabetes or diabetic patients not on insulin. The study highlighted the importance of considering insulin-requiring diabetes as an independent factor affecting clinical outcomes in AF patients on edoxaban. [Extracted from the article]

A recent study conducted at Federal University Ceara in Brazil focused on Alzheimer's disease immunotherapy and the design of mimetic peptides for drug development. The study highlighted the use of Aducanumab and lecanemab, novel disease-modifying antiamyloid-beta human monoclonal antibodies, in the treatment of Alzheimer's disease. The research employed mutation screening, molecular dynamics, and quantum biochemistry to identify critical stabilizing contacts and design mimetic peptides that have the potential to inhibit A beta aggregation, showing promise as inhibitors of the disease. The study was supported by financial assistance from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) and has been peer-reviewed. [Extracted from the article]

A preprint abstract discussed in Drug Week explores the development of a synthetic chaperone, inspired by Hsp90-Tau interactions, to inhibit pathological Tau aggregation in Alzheimer's disease. The innovative peptidomimetic, named {beta}-Hsp90, effectively prevents Tau aggregation and restores its interaction with microtubules, potentially offering a dual inhibitor for AD-associated A{beta}1-42 aggregation. This research suggests a promising strategy for designing new drugs targeting amyloid diseases by mimicking physiological chaperones with small synthetic peptide drugs. [Extracted from the article]

A study conducted by researchers at Beijing University of Chemical Technology explores the molecular mechanisms underlying insulin analogs, specifically insulin aspart (IAsp) and insulin degludec (IDeg). These insulin analogs have distinct release profiles and are synthesized through targeted mutagenesis in protein engineering. The study utilizes molecular dynamics simulation and experimental verification to investigate the structural stability, solubility analysis, and monomer interactions of these insulins, providing insights into the differences in their release mechanisms. The findings shed light on the intricate mechanisms underlying insulin release and have potential implications for the design of insulin therapy. [Extracted from the article]

A recent study conducted by researchers at the Central Arkansas Veterans Healthcare System aimed to determine the frequency and determinants of levothyroxine therapy initiation for veterans with subclinical hypothyroidism (SCH). The study found that 27.5% of veterans with SCH were treated with levothyroxine. Factors associated with higher odds of treatment included being White and having a higher thyrotropin level. The study suggests potential disparities and the influence of SCH severity on treatment decision-making. Further research is needed to better understand the reasons behind these findings. [Extracted from the article]

A recent study conducted by researchers at Shanghai Jiao Tong University in China explores a new approach to tumor therapy using metal-anesthetic networks coated with dormant collagenase-producing bacteria. The researchers found that this method effectively destroys tumor matrix and inhibits tumor metastasis. By selectively germinating and proliferating in tumor sites, the coated bacteria produce collagenases to degrade tumor collagen mesh and inhibit tumor cell migration and invasion. The study suggests that this strategy could be a promising avenue for the development of advanced therapeutics for malignant tumor treatment and metastasis prevention. [Extracted from the article]

A recent study conducted at Monash University explored the role of glucagon, a peptide hormone, in metabolic regulation and its potential as a therapeutic option for obesity and type 2 diabetes. The researchers used liver phosphoproteomics to identify glucagon signaling nodes and found that phosphorylation of the vesicle trafficking protein SEC22B played a major role in glucagon action. They also identified protein binding partners of SEC22B affected by glucagon. This study provides valuable insights into the biology of glucagon action and its metabolic effects. [Extracted from the article]

According to a preprint abstract, cancer survivors treated with cisplatin, a common chemotherapy drug, have a higher risk of developing metabolic syndrome and Type 2 diabetes compared to the general population. The study aimed to determine the effects of cisplatin on pancreatic islet function in male mice. The results showed that both direct and systemic exposure to cisplatin caused acute defects in insulin secretion and may have lasting effects on islet health. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent report from the National Research and Innovation Agency (BRIN) discusses the production of insulin glargine, a long-acting insulin analogue, using Pichia pastoris. The study aimed to increase the yield of insulin glargine by evaluating the effects of different mediums and vitamins on cell growth and insulin glargine expression levels. The findings revealed that the addition of vitamins to the mediums increased insulin glargine production. The research concludes that the addition of vitamins enhances the production of insulin glargine. [Extracted from the article]

A recent study conducted at King Saud University Medical City in Saudi Arabia examined the effects of metformin on neonatal outcomes in patients with gestational diabetes mellitus (GDM). The study included 234 women with GDM who were treated with specialized diets, metformin, or insulin. The results showed that there was no significant difference in neonatal outcomes between the metformin and insulin groups. However, the metformin group had higher rates of neonatal hypoglycemia, neonatal hyperbilirubinemia, large for gestational age, respiratory distress, and a slightly increased risk of a lower APGAR score compared to the diet group. The researchers concluded that metformin is a safe therapy for managing GDM in terms of fetal outcomes, but more randomized studies are needed to confirm these findings in the Saudi population. [Extracted from the article]

A recent study conducted in Higashiosaka, Japan, explored the use of plasma renin activity (PRA) as a biomarker for predicting the antihypertensive effect of switching to sacubitril/valsartan (Sac/Val) in patients with treated hypertension. The study found that clinic blood pressure significantly decreased after switching to Sac/Val, and PRA before drug switching was significantly correlated with the change in systolic blood pressure. The researchers concluded that low PRA may be a useful marker for predicting the antihypertensive effect of switching to Sac/Val in treated hypertensive patients. This research has been peer-reviewed and published in The Journal of Clinical Hypertension. [Extracted from the article]

Osaka University in Japan has successfully developed a prototype device for the first made-in-Japan biomolecular sequencer. Biomolecular sequencers are important tools for gene-based cancer diagnosis and treatment, as they can determine the base sequences of DNA and RNA, as well as the amino acid sequences of peptides. The research team collaborated with H.U. Group Research Institute and Sony Global Manufacturing & Operations Corporation to overcome the challenges of developing a measurement chip and measurement device for practical application. The team plans to continue developing AI optimized for biomolecular sequencers and a peptide sequencer for peptide drug discovery. [Extracted from the article]